杭州壹瑞医药

Hangzhou Yirui Pharmaceutical is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company leverages a proprietary structure-based drug design (SBDD) platform to create highly selective oral treatments that aim to replace traditional injectable biologics. Its lead candidate, YR-001, is a potent small molecule GLP-1 receptor agonist currently undergoing Phase 1 clinical trials for the treatment of type 2 diabetes and obesity. Yirui Pharma is focused on addressing significant unmet medical needs by improving patient compliance through convenient oral dosing. The company is backed by leading venture capital firms, including Qiming Venture Partners and TF Capital.